Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope 

The scope of the project will be to create a non-exhaustive first set of technical conformance rules with the tumor.xpt specification.


Project Problem Statement 

Since 1999, the FDA has requested that industry provide tumour data from nonclinical studies in a specified format (‘tumor.xpt’). This data is now submitted jointly with SEND datasets. Where the SEND standard comes with a set of conformance rules from CDISC, the tumor.xpt specification does not have these, and consequently this file, unlike the adjoining SEND datasets, is not currently validated using out-of-the-box tools. Since the tumor.xpt format is not a CDISC standard, it is confirmed that the CDISC SEND team will NOT provide such conformance rules with the tumor.xpt format. Consequently, there is currently a manual burden on industry to verify the adherence of the tumor.xpt file to the FDA specification.


Project Problem Impact 

This project will provide the first set of validator rules to be implemented by tools already used by the industry for verification of SEND datasets, thus removing part of the current manual burden of reviewing this file. The benefit for industry, with an automation of these checks, will be increased quality of the tumor.xpt file and reduced time to generate it. With an increased quality of the tumor.xpt file, it is expected that less communication will be needed between sponsors and the FDA to discuss potential issues with the tumor.xpt file. Should the FDA decide to adopt these conformance rules, they can benefit by getting an early insight into any potential issues they could encounter when reviewing the data, thus also increasing actual data review time and not spending it on identifying and correcting issues with the format.



Project LeadsEmail 
Gitte Frausing, (Data Standards Decisions)

gfrausing@datastandardsdecisions.com

Hepei Chen, (FDA)

hepei.chen@fda.hhs.gov

Katie Warren (PHUSE Project Assistant)

katie@phuse.global


Objectives & DeliverablesTimelines
Kick off meeting and agree on a regular meeting schedule Q2 2023


Status
colourBlue
titleCurrent Status
Q1 2023

Project approved. Kick off will take place early May 2023.



Project Members Organisation
Benjamin Sefing 

Merck

Christy Kubin 

Charles River Laboratories 

David Epstein

FDA

Erin Tibbs-Slone 

Charles River Laboratories 

Jesse Anderson

FDA

Julie Anne Hood

Pinnacle21

Lou Ann Kramer

CDISC

Saga Darekar

Instem